secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001213900-22-023584
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points
--------------------------------------------------------------------------------

- Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.
- Net loss $4.1M ($0.38/share) vs $2.5M ($0.24) in Q1 2021; R&D expenses rose to $2.7M from $1.3M.
- RADR AI platform surpassed 20 billion data points; on track for 25 billion by year-end 2022.
- IND for LP-184 targeted for Q3 2022; HARMONIC Phase 2 trial for LP-300 expected to start enrollment summer 2022.
- Share repurchase program extended; $3.6M remaining authorized through July 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022023584/0001213900-22-023584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022023584/ea159290-8k_lantern.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-023584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer